US Stem Cell Inc (OTCMKTS:USRM) Keeps Rewarding Dip Buyers

In our last article about US Stem Cell Inc (OTCMKTS:USRM), we noted the positive reaction to its Q1 2017 earnings and the payment of its convertible debt. We also said that the company had become popular on social media. All these developments made the share price rise in mid May.Lately, we saw some profit taking since the share price went from $0.13 to $0.09 on light volume. We believe that this decline was more of a technical decline as no bad news was reported by the company. It was actually a nice time to buy the dip, as the share went back up from $0.08 to almost $0.11 very recently.Why?We found no news, or earnings release put out by the company. But, we found out that the Chief Science Officer, Ms. Comella, was interviewed by Natural health expert and Mercola.com founder, Dr. Joseph Mercola. Perhaps, the market may have reacted to it. In this article, we will assess it. Also, will will analyze the most important points noted by this expert.SourceHave a look at the long term performance of the stock. Our regular readers and subscribers have done quite well following our lead on USRM, which we have covered since March (you can read all the articles here):Additionally, the interview was published on May 31, 2017. The share price reacted to it on June 1, 2017 once the market opened.SourceRecent DevelopmentsFirst up, here is some background. USRM is a biotechnology company researching and developing cell therapies for the treatment of chronic and acute heart damage. The company was founded in 1999, and incorporated in the State of Florida. It was originally called Bioheart, Inc., and the name change to U.S. Stem Cell, Inc. was executed in 2015. It is headquartered in Florida.The person giving the answers about US Stem Cells is Kristin C Comella, the Chief Science Officer. We are now making a quick review of her profile as it appears in the company website. She is a "world renowned expert on regenerative medicine with a focus on adipose derived stem cells, number 1 on the Academy of Regenerative Practices list of Top 10 Stem Cell Innovators". She was the person in the company who led the team that gained the the first ever FDA approval for a clinical trial using a combined cell and gene therapy product in the heart. Additionally, she has a lot of experience of working in health care that include positions in Stemlogix, Tulane University, and Osiris Therapeutics. These are some of her posts and academic recognitions:

• Co-founder and Chief Executive Officer of Stemlogix
• Chief Scientific Officer and board member of US Stem Cell
• Research engineer at Osiris Therapeutics
• PhD candidate in Biomedical Engineering at Florida International University
• M.S. in Chemical Engineering from The Ohio State University
• B.S. in Chemical Engineering from the University of South Florida.

In the interview, Ms. Comella explains what stem cells are and how the company's treatment works. She explained that stem cells are in every human body, and they are created every two hours. The treatment helps in introducing new ones. Additionally, it was noted that the company does not sell a magic product; the patients also need to control the amount of toxins received by the body in order to repair damaged tissues with the help of stem cells. Furthermore, it was said that the treatment usually takes several months and several doses to work. It is a slow process.The most important part of the video was when Ms. Comella explained her personal experience using the company's products. She explained that she has been taking doses for many years, and the treatment really works if used for a long period of time to reduce the inflammation in the tissues. Also, she stated, as she believes, that the product strengthens lifespan, "she takes doses once every six to twelve months regardless of what is going on".ConclusionChief Science Officer, Ms. Comella, appeared in a 48 minute interview with Dr. Joseph Mercola from Mercola.com. In the interview, the products being developed by the company were noted again and the personal experience of the executive was introduced. The market seemed to appreciate the initiative and traders pushed the share price up again. Hence, stem cell seem to be more and more understood everyday, which may increase the revenues in the long term. To sum up, stay alert about this company, as the each sell off keeps rewarding the dip buyers. We will be updating our subscribers as soon as we know more. For the latest updates on USRM, sign up below!Disclosure: We have no position in USRM and have not been compensated for this article.